क्षेत्र

औषधि खोज

लक्ष्य, अणु, और चार्ट को परीक्षण से मिलाना।

2 परिदृश्य

औषधि खोज

प्रकाशित

A generative-AI-designed molecule in a phase 2a IPF trial

Insilico Medicine used a generative platform to propose TNIK as a target in idiopathic pulmonary fibrosis and to design rentosertib (formerly ISM001-055). Nature Medicine published a 12-week randomized phase 2a trial in 2025. The primary endpoint was safety, not lung function. The molecule is investigational. A small secondary signal is not an approved therapy.

Pharma.AI · Insilico Medicine · rentosertib (ISM001-055)

पत्र · 2025मामला पढ़ें

औषधि खोज

Matching a cancer chart to trial eligibility

Trial-matching tools read structured fields and sometimes the free-text note to list studies a patient might qualify for. Tempus, Flatiron, and Deep 6 AI are examples of companies that sell a version of this. A research coordinator still checks every criterion against the chart. A match list is not enrollment, and it is not a treatment recommendation.

Tempus · Flatiron · Deep 6 AI

विक्रेता · 2025मामला पढ़ें